{
  "subset": "contraindication",
  "disease": "Hyperammonaemia",
  "relation": "contraindication",
  "gold_drugs": [
    "buphenyl",
    "carglumic acid",
    "disodium",
    "drugs inducing hyperammonemia",
    "fezagepras",
    "glutamine",
    "hpn-100",
    "mnk-6105",
    "napba",
    "ornithine alpha ketoglutarate",
    "ornithine phenylacetate",
    "placebo intravenous infusion",
    "ravicti",
    "sodium benzoate",
    "sodium phenylbutyrate",
    "standard of care",
    "tnp-2092 capsules",
    "tnp-2092 placebo capsules",
    "vitamin e"
  ],
  "seeds_initial": [
    "Sodium Benzoate",
    "Phenylbutyrate",
    "Lactulose",
    "N-acetylcysteine",
    "Valproic Acid",
    "Rifampin",
    "Acetaminophen",
    "Phenobarbital",
    "Nitrofurantoin",
    "Zonisamide",
    "Topiramate",
    "Sodium Valproate"
  ],
  "seed_history": [
    [
      "Sodium Benzoate",
      "Phenylbutyrate",
      "Lactulose",
      "N-acetylcysteine",
      "Valproic Acid",
      "Rifampin",
      "Acetaminophen",
      "Phenobarbital",
      "Nitrofurantoin",
      "Zonisamide",
      "Topiramate",
      "Sodium Valproate"
    ],
    [
      "Sodium Benzoate",
      "Lactulose",
      "Ammonul",
      "Carbaglu",
      "L-Carnitine",
      "Arginine",
      "N-acetylglutamate",
      "Phenylbutyrate",
      "Glutamate",
      "Tetrahydrobiopterin",
      "Citrulline",
      "Urea"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_sodium_benzoate",
          "name": "Sodium Benzoate"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H1_round5",
        "key_assumptions": [
          "对氨基酸代谢的干预支持机制推论",
          "潜在的安全风险需被考虑"
        ],
        "caveats": [
          "不良表型的风险可能抵消有效性"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_lactulose",
          "name": "Lactulose"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H2_round5",
        "key_assumptions": [
          "理论上符合氨中毒治疗的机理",
          "潜在安全性问题需关注"
        ],
        "caveats": [
          "不良效果风险可能影响临床应用"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_ammonul",
          "name": "Ammonul"
        },
        "score": 0.42,
        "graph_snapshot_ref": "GE_H3_round5",
        "key_assumptions": [
          "可用于氨中毒治疗的可能性"
        ],
        "caveats": [
          "支持证据有限，风险需谨慎评估"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Risk pathways associated with Sodium Benzoate and Lactulose leading to adverse phenotypes",
          "reason": "安全性主导因素对推荐的影响"
        }
      ],
      "remaining_gaps": [
        "缺乏机制支持的证据，需进一步验证"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": []
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that are contraindicated or could worsen the rare disease 'Hyperammonaemia'. Return only names.\n\n# Prior guidance for Explorer:\n- Generate novel candidates that might provide additional detoxification pathways without overlapping existing ones.\n\n# Heuristics:\n- When Hyperammonaemia treatment: then Evaluate intervention efficacy versus documented adverse effects for holistic patient management."
}